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Abstract
Background: Interstitial cystitis is a chronic condition associated with bladder inflammation and,
like a number of other chronic pain states, symptoms associated with interstitial cystitis are more
common in females and fluctuate during the menstrual cycle. The aim of this study was to
determine if estrogens could directly modulate signalling pathways within bladder sensory neurons,
such as extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases.
These signalling pathways have been implicated in neuronal plasticity underlying development of
inflammatory somatic pain but have not been as extensively investigated in visceral nociceptors. We
have focused on lumbosacral dorsal root ganglion (DRG) neurons projecting to pelvic viscera (L1,
L2, L6, S1) of adult female Sprague-Dawley rats and performed both in vitro and in vivo manipulations
to compare the effects of short- and long-term changes in estrogen levels on MAPK expression and
activation. We have also investigated if prolonged estrogen deprivation influences the effects of
lower urinary tract inflammation on MAPK signalling.
Results: In studies of isolated DRG neurons in short-term (overnight) culture, we found that
estradiol and estrogen receptor (ER) agonists rapidly stimulated ER-dependent p38
phosphorylation relative to total p38. Examination of DRGs following chronic estrogen deprivation
in vivo (ovariectomy) showed a parallel increase in total and phosphorylated p38 (relative to β-
tubulin). We also observed an increase in ERK1 phosphorylation (relative to total ERK1), but no
change in ERK1 expression (relative to β-tubulin). We observed no change in ERK2 expression or
phosphorylation. Although ovariectomy increased the level of phosphorylated ERK1 (vs. total
ERK1), cyclophosphamide-induced lower urinary tract inflammation did not cause a net increase of
either ERK1 or ERK2, or their phosphorylation. Inflammation did, however, cause an increase in
p38 protein levels, relative to β-tubulin. Prior ovariectomy did not alter the response to
inflammation.
Conclusions: These results provide new insights into the complex effects of estrogens on bladder
nociceptor signalling. The diversity of estrogen actions in these ganglia raises the possibility of
developing new ways to modulate their function in pelvic hyperactivity or pain states.
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Background
Interstitial cystitis is a chronic condition associated with
inflammation of the lower urinary tract, which is more
common in women and causes bladder symptoms (e.g.,
increased urgency and frequency) and pain that are poorly
treated [1-3]. While there is considerable debate sur-
rounding the diagnosis and etiology of interstitial cystitis,
bladder tissues often show inflammation and ulceration
[4,5]. During this period, it is likely that nociceptive C-fib-
ers within the bladder wall become sensitised by neuro-
trophic factors and other inflammatory mediators [6-9].
Like a number of other chronic pain states, symptoms
associated with interstitial cystitis are more common in
females and fluctuate during the menstrual cycle [6,10].
Moreover, following ovariectomy, mice develop hyperal-
gesia and enhanced visceral sensitivity [11,12]. These
observations raise the question of the mechanisms by
which estrogens could be modulating pain and, more spe-
cifically, bladder pain.
Neuroanatomical studies have identified estrogen recep-
tors (ERs) and ER mRNA within many small- and
medium-sized lumbosacral dorsal root ganglion (DRG)
neurons [13-15]. Evidence supporting a direct effect of
estrogens on bladder nociception was provided by Ben-
nett and colleagues, showed that in adult female rat lum-
bosacral DRG, ERα and ERβ are synthesised by more than
half of the bladder-projecting neurons identified by retro-
grade tracer [16]. Moreover, about one-third of these neu-
rons express both ERs and the nociceptive transducer,
transient receptor potential vanilloid receptor 1 (TRPV1),
providing a mechanism by which steroid modulation
could directly affect bladder pain. More recently, an ERβ-
dependent effect of estradiol on nociceptor activity has
been identified in adult female rat lumbosacral DRG neu-
rons, where overnight exposure to estradiol or ERβ-ago-
nist powerfully reduces the effects of capsaicin [17]. There
is also a large body of evidence supporting rapid actions
of estrogens within the nervous system (see review [18]),
including the regulation of nociception and pelvic visceral
pain. For example, in adult rat lumbosacral DRG neurons,
estradiol rapidly induces activation of extracellular signal-
regulated kinases (ERK), in turn leading to phosphoryla-
tion of cAMP response element binding protein (CREB)
[19]. CREB has been strongly linked to neuronal plasticity
including long term potentiation [20], so could partici-
pate in sensitisation, as demonstrated in the dorsal horn
[21].
ERK activation has been causally linked to the develop-
ment of pain [22], being elevated in nociceptor neurons
and spinal cord after inflammatory stimuli and peripheral
nerve trauma, including a model of acute visceral pain
[23-27]. Chronic visceral inflammation causes a pro-
longed increase in phosphorylated ERK within the blad-
der tissues [28]. Moreover, elevated levels of nerve growth
factor (NGF) within the inflamed bladder [29] and
increased expression of neurotrophic factor receptors in
bladder afferent neurons of rats with cystitis [30] could
provide a mechanism for mediating this effect on ERK sig-
nalling. Irrespective of the mechanism, an important role
of mitogen-activated protein (MAP) kinases is indicated
by studies showing that intravesical or intrathecal admin-
istration of MEK inhibitors increases bladder capacity in
rats with cystitis [28,31]. A second family of MAP kinases,
the p38 MAP kinases, have been implicated in neuronal
plasticity underlying development of inflammatory and
neuropathic pain. This pathway can be activated by
cytokines, leading to hyperexcitability and repetitive firing
of nociceptors in DRG. For example, tissue-derived NGF
drives a p38-dependent expression of TRPV1 [32] and p38
causes phosphorylation and increased current density of
the sodium channel, Nav1.8 [33]. These actions have not
yet been investigated in visceral nociceptors.
While estrogen has been proposed to affect neuroinflam-
mation of the bladder by influencing NGF activity [6], it is
also possible that estrogens affect bladder pain by directly
modulating signalling pathways within bladder sensory
neurons. We have focused on lumbosacral DRG neurons
projecting to pelvic viscera (L1, L2, L6, S1) of adult female
Sprague-Dawley rats and performed both in vitro and in
vivo manipulations to address the following aims: (i) to
determine if estradiol acutely modulates p38 signalling in
vitro; (ii) to investigate whether chronic estrogen depriva-
tion in vivo (ovariectomy) affects p38 or ERK activity, (iii)
to determine if chronic bladder inflammation affects p38
or ERK activity and (iv) if prior ovariectomy attenuates or
enhances any effects initiated by bladder inflammation.
We identified distinct effects of acute and chronic estra-
diol manipulation on p38 MAP kinase in DRGs. Moreo-
ver, while inflammation and ovariectomy both caused
some effects on MAP kinases, the nature of these effects
differed between p38 and ERK1/2 MAP kinases. These
results provide new insights into the complex effects of
estrogens on bladder nociceptor signalling.
Methods
A total of 22 female Sprague-Dawley rats (6-13 weeks old)
were used for this study. For in vitro studies, animals were
6-7 weeks old at the time of tissue removal. The in vivo
studies were designed such that the manipulations were
commenced at a similar age (6-7 weeks old) and tissues
removed at 9-13 weeks of age (depending on treatment
group; see below). Rats were obtained from Animal
Resources Centre (Perth, Australia) and all procedures
were approved by the University of Sydney and Royal
North Shore Hospital ethics committees, and conducted
in accordance with the Australian Code of Practice for the
Care and Use of Animals for Scientific Purposes (National
Health and Medical Research Council of Australia) and
the National Institutes of Health Guide for the Care andBMC Neuroscience 2009, 10:156 http://www.biomedcentral.com/1471-2202/10/156
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Use of Laboratory Animals. All efforts were made to min-
imize the number of animals used and their suffering. The
estrous cycle of the animals was monitored but not con-
trolled for in these experiments. We did not observe any
effects of estrus cycle stage for any of the parameters meas-
ured so the results were pooled. Much larger numbers of
animals would be required to exclude or confirm an effect
of estrus cycle on our measurements.
In vitro studies
Rats were heavily anaesthetized with sodium pentobarbi-
tone (80 mg/kg) then decapitated. Dorsal root ganglia
(DRG) were cultured and prepared for Western blotting
analyses as described previously [17,19]. Briefly, DRG
were dissected from spinal levels L1, L2, L6 and S1, the
capsule was quickly removed from each ganglion under a
dissecting microscope, ganglia pooled and transferred
into modified Tyrodes solution containing (mM) NaCl
130, NaHCO3 20, KCl 3, CaCl2 4, MgCl2 1, HEPES 10, glu-
cose 12 with antibiotic-antimycotic solution. DRGs were
then treated with collagenase (Type I, Worthington Bio-
chemical Corporation, West Chester, PA) and trypsin
(0.25%, Invitrogen, Mt Waverley, Australia) at 37°C for 1
h, washed, triturated, overlayed on bovine serum albumin
(15%, Sigma, Castle Hill, Australia) and centrifuged at
900 rpm for 10 min to remove myelin and debris. The pel-
let was resuspended with Neurobasal A and B27 (Invitro-
gen) and for Western blotting studies, neurons plated
onto disposable plastic Petri dishes, previously coated
with polyornithine (Sigma) and laminin (Invitrogen). For
immunohistochemistry, neurons were plated onto glass
coverslips similarly coated with polyornithine and lam-
inin. The neurons were maintained at 37°C in a humidi-
fied atmosphere containing 5% CO2 for 18-24 h before
use, to minimize any acute effects of dissociation (e.g.
axotomy) on cell signaling [34]. Cultures were then
treated with appropriate reagents added to the culture
medium as indicated for each experiment in the Results.
At the end of treatment, the culture was washed once with
cold phosphate-buffered saline (PBS; 0.1 M, pH 7.2), then
200 μl ice-cold T-PER protein extraction reagent (Pierce,
Rockford, IL) containing a standard protease inhibitor
cocktail (Complete Mini; Roche, Castle Hill, NSW, Aus-
tralia) and phosphatase inhibitor cocktail (PhosSTOP,
Roche) was added. Cultured cells were removed with a
cell scraper, briefly sonicated and centrifuged at 10,000 g
for 5 min; the supernatant was collected and stored at -
20°C for Western blotting. All culture experiments con-
tained an internal control (treated only with vehicle),
each sample was tested in duplicate and each experiment
was replicated three times.
Immunohistochemistry
Cultures were fixed in 4% phosphate-buffered parafor-
maldehyde for 30 min, blocked and permeabilised in
phosphate buffered saline (PBS) containing 10% horse
serum and 0.1% triton X-100 for 1 h, then incubated with
primary antibodies for 2 h. Antisera against the following
antigens were used: β-tubulin isotype type III (1:200; host
species, mouse; Sigma-Aldrich, Castle Hill, Australia),
ERα (1:250; host species, rabbit; Affinity Bioreagents,
Golden, CO), ERβ (1:400; host species, chicken; gift from
JA Gustafsson, Karolinska Institute, Stockholm). Cultures
were then incubated with Cy3- or FITC-tagged secondary
antibodies (Jackson Immunoresearch Laboratories, West
Grove, PA, USA) for 1 h. DAPI (4',6-diamidino-2-phe-
nylindole dihydrochloride;1 μg/ml, Sigma) was used as a
nuclear counterstain. Coverslips were mounted onto
slides in 0.5 M bicarbonate-buffered glycerol (pH 8.6)
and viewed with an Olympus BX-51 fluorescence micro-
scope. Images (8-bit monochrome) were captured using
an RT Spot camera (Diagnostic Instruments, Sterling
Heights, MI, USA) and digitised using Image Pro Plus soft-
ware (Media Cybernetics, Silver Spring, MD, USA). For
figure production, minor adjustments were made to con-
trast and brightness of the entire image, to best represent
the immunostaining as viewed under the microscope,
using Adobe Photoshop (Version CS3).
In vivo studies
Four groups of rats were studied: control (n = 4), ovariec-
tomy (OVX; n = 4), cyclophosphamide-treated (CYP, n =
5) and ovariectomy prior to cyclophosphamide treatment
(OVX-CYP, n = 3). For the ovariectomy group, rats were
anaesthetised with ketamine (60 mg/kg i.p.) and xylazine
(10 mg/kg i.p.) prior to performing a bilateral ovariec-
tomy. Four weeks later rats were deeply anaesthetised with
sodium pentobarbitone (80 mg/kg, i.p.) and DRG (L1,
L2, L6, S1) removed and pooled for protein extraction as
described above. Tissues from age-matched intact controls
were also removed at this time. A second experimental
group of rats was treated with cyclophosphamide (CYP)
to induce inflammation of the lower urinary tract [35,36].
To administer CYP, animals were briefly anaesthetised
with isoflurane then injected with CYP in sterile 0.9%
sodium chloride (75 mg/kg, i.p), every three days [30].
On day 10, animals were heavily anaesthetised with
sodium pentobarbitone as above, and DRG removed and
pooled for protein extraction as above. For the OVX-CYP
group, rats were ovariectomised and four weeks later CYP
treatment was administered as above, then DRG removed
for protein studies. DRGs were placed in 200 μl ice-cold T-
PER protein extraction reagent (Pierce, Rockford, IL) con-
taining a standard protease inhibitor cocktail (Complete
Mini; Roche, Castle Hill, NSW, Australia) and phos-
phatase inhibitor cocktail (PhosSTOP, Roche), and
homogenized on ice for at least 1 min. Homogenized
samples were centrifuged at 10,000 g for 5 min to pellet
tissue debris. Supernatant was collected and stored at -
20°C in aliquots for Western blotting.BMC Neuroscience 2009, 10:156 http://www.biomedcentral.com/1471-2202/10/156
Page 4 of 10
(page number not for citation purposes)
Western blotting
Protein extracted from freshly dissected or cultured DRGs
was mixed with protein loading buffer and heated at 99°C
for 3 min, and then kept on ice, until loaded and sepa-
rated on 12% sodium dodecyl sulfate-polyacrylamide gel
(SDS-PAGE; ~10 μg per well). Proteins were then trans-
ferred onto PVDF membrane for 2 h on ice and the mem-
brane with transferred proteins then blocked with 5%
non-fat milk solution in TBS/Tween (TBST) for 1 hr at
room temperature. The membrane was then washed and
incubated overnight at 4°C with an antibody raised in
rabbit against phospho-p38 (Cell Signaling Technology,
Danvers MA; 1:1,000 in TBST with 5% BSA) or phospho-
ERK1/2 (Cell Signaling Technology, 1:4,000 in TBST with
5% milk). After washing, the membrane was incubated
with horseradish peroxidase-conjugated anti-rabbit IgG
(1:50,000 in TBST with 5% milk; Jackson ImmunoRe-
search) for 1 h at room temperature. A single band (38
kDa) for phospho-p38 or double bands (44 and 42 kDa)
for phospho-ERK1/2 were visualized using ECL plus
(Amersham, now GE Healthcare). The membranes were
stripped with stripping buffer (7 μl 2-mercaptoethanol
per ml TBST with 2% SDS) for 30 min and rinsed with
TBST for 30 min. The membrane was re-blotted with pri-
mary antibody against total p38 (Cell Signaling; 1:1,000
in TBST with 5% BSA) or total ERK1/2 (Cell Signaling;
1:4,000 in TBST with 5% milk) overnight at 4°C, and
incubated with horseradish peroxidase-conjugated anti-
rabbit IgG as above. A single band (38 kDa) for p38 or
double bands (44 and 42 kDa) for ERK1/2 were visualized
with ECL plus. Band densities were converted to numeri-
cal values using Quantity One (Biorad, Hercules, CA),
subtracting background values from an area of gel imme-
diately adjacent to the stained band. Exposure times were
chosen to avoid pixel saturation.
Data are expressed as the ratio of phosphorylated p38 or
ERK against total p38 or ERK for each sample.
For freshly dissected DRG removed from the four in vivo
treatment groups, there was sufficient protein available in
each sample to allow more than one aliquot to be stored
from each animal. This minimised the need for animals in
the control group. There were insufficient wells available
to run all samples from all groups on one gel, so samples
were grouped as follows: Run 1 comprised all samples
from control and OVX groups; Run 2 comprised all sam-
ples from control, CYP and CYPOVX groups. Because
long-term treatments (CYP, OVX, CYPOVX) could affect
neuronal structure and growth, we also measured β-tubu-
lin in each of these samples; this also allowed for any
minor variations in tissue dissection or preparation. Gels
were divided into two sections to allow separate process-
ing for P-p38/p38 (~38 kDA) and β-tubulin (~50 kDa),
based on their different migration speed on gels. One
membrane section was processed for P-p38 and p38 as
described above and the other half was probed for β-tubu-
lin (1:10,000, host mouse; Sigma-Aldrich, Castle Hill,
Australia) and anti-mouse IgG (1:50,000; Jackson Immu-
noResearch). The results from our in vivo experiments
have been expressed as raw values for phosphorylated and
total ERK (or p38) MAP kinase relative to β-tubulin levels
in the same sample. We have also calculated the ratio of
phosphorylated to total ERK1, ERK2 or p38 MAP kinase.
Statistics
All values are expressed as mean ± SE. Analyses were per-
formed with Graphpad Prism (Graphpad Software, San
Diego CA). Effects of treatments were compared by
unpaired 2-tailed t-test or, for comparison of more than
two groups, ANOVA followed by Tukey's test. Significance
was accepted if P < 0.05.
Drugs and chemicals
Unless otherwise stated, all reagents were purchased from
Sigma-Aldrich. Diarylpropionitrile (DPN), propyl pyra-
zole triol (PPT) and tamoxifen were purchased from Toc-
ris (Ellisville, MO). ICI 182,780 was a gift of AstraZeneca
(North Ryde, Australia).
Results
17β-Estradiol rapidly activated p38 MAPK by an estrogen 
receptor-dependent mechanism in cultured DRG
Treatment of DRG cultures with 17β-estradiol (10 nM;
E2) activated p38 MAPK within 10 minutes (Fig. 1A, B).
That is, there was an increase in phospho-p38 compared
with total p38 protein. This effect was mimicked by the
specific estrogen receptor (ER) agonists, PPT (ERα agonist,
10 nM) and DPN (ERβ agonist, 10 nM) (Fig. 1A). We then
tested if the effects of E2 would be inhibited by the pure
ER antagonist, ICI182,780 (3 μM) or the estrogen receptor
modulator, tamoxifen (1 μM), which antagonises estro-
gen responses in many tissues. This set of experiments
showed that while tamoxifen abolished the response to
E2, ICI182,780 not only failed to attenuate the E2
response but itself activated p38 MAPK (Fig. 1B).
We then examined our cultures immunohistochemically
to confirm that estrogen receptors (ERs) were expressed by
adult rat DRG neurons in culture and to investigate the
possibility of estrogen action on glial cells. Neurons were
distinguished from glia by their immunoreactivity for β-
tubulin and distinctive properties of their nuclei identi-
fied by DAPI. Neuronal nuclei were large with pale DAPI
staining, and easily distinguished from glial cell nuclei
that were smaller, ovoid and more intensely stained [19].
After 24 h in culture, less than half of the neurons had
grown neurites, but many of these possessed long,
branching processes (Fig. 2A). ERα-immunoreactivity was
identified in many but not all neuronal nuclei (Fig. 2B).BMC Neuroscience 2009, 10:156 http://www.biomedcentral.com/1471-2202/10/156
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Weak ERα-immunoreactivity was also present in the cyto-
plasm of many somata but was rarely evident within neu-
rites. ERβ-immunoreactivity was identified in many
neuronal nuclei and within the soma cytoplasm, and
punctate ERβ-immunoreactivity was present in many neu-
rites (Fig. 2C). Neither ERα- nor ERβ-immunoreactivity
were evident in glial cells (Fig. 2D, E). We did not quantify
the proportion of neurons expressing ERs because many
neurons showed relatively dim immunoreactivity and we
could not confidently determine how many of these
should be considered as genuinely ER-immunoreactive.
Together, these two experiments revealed a rapid ER-
dependent effect of E2 on p38 activation in DRG neurons
and suggest that a novel mechanism underpins this
action.
Phosphorylation of p38 MAP kinase in cultured adult rat  DRG neurons following treatment with ER agonists and  antagonists (10 min) Figure 1
Phosphorylation of p38 MAP kinase in cultured adult 
rat DRG neurons following treatment with ER ago-
nists and antagonists (10 min). A, 17β-Estradiol (E2), 
PPT and DPN (each 10 nM) all stimulated p38 phosphoryla-
tion (separate cultures from 3 rats). A representative West-
ern blot is shown below. B, E2 (10 nM) stimulated p38 
phosphorylation that was prevented by tamoxifen (tx; 1 μM) 
and mimicked by ICI182,780 (ICI; 3 μM). The response to E2 
with ICI182,780 was greater than with E2 alone. Tamoxifen 
alone had no effect. Data comprises separate cultures from 3 
rats, expressing phosphorylated p38 relative to total p38 
protein. A representative Western blot is shown below. * P 
< 0.05, ** P < 0.01, *** P < 0.001, relative to control; # P < 
0.05 relative to E2.
Adult female rat dorsal root ganglion (DRG) neurons cul- tured overnight in the absence of serum or added neuro- trophic factors Figure 2
Adult female rat dorsal root ganglion (DRG) neurons 
cultured overnight in the absence of serum or added 
neurotrophic factors. a, Cultured DRG neuron immunos-
tained for β-tubulin, showing extensive neurite growth. b, 
Two neurons showing immunoreactivity for ERα in the 
nucleus (arrows) and one neuron (bottom left) with no 
nuclear immunostaining. c, Neuron showing bright immuno-
reactivity for ERβ in the nucleus (arrow), moderate immuno-
reactivity in the cytoplasm and faint punctate staining in some 
neurites. d, e shows the same neuron, immunostained for 
ERα d) and nuclei labelled with DAPI (e); ERα-immunoreac-
tivity is present in the neuronal nucleus (arrow) but not in 
the closely associated glia. Immunohistochemistry was per-
formed in separate cultures from 3 rats. Calibration bar rep-
resents 20 μm (a-c), 10 μm (d, e).BMC Neuroscience 2009, 10:156 http://www.biomedcentral.com/1471-2202/10/156
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Chronic estrogen deprivation enhanced p38 MAPK 
expression and ERK1 phosphorylation
Although the initial in vitro studies revealed rapid-onset
activation of p38 MAPK signalling by E2, the long-term
effects of changing estrogen exposure in vivo are of consid-
erable physiological interest. We therefore compared the
effects of prolonged estrogen deprivation (4 weeks post-
ovariectomy) on the expression and activation of p38
MAPK within extracts of lumbosacral DRG, focusing on
those spinal levels that innervate the urinary bladder (Fig.
3A). Relative to β-tubulin, both total and phosphorylated
p38 were increased by ovariectomy, but the ratio of phos-
phorylated p38 to total p38 protein remained unchanged.
In contrast, ovariectomy did enhance ERK1 phosphoryla-
tion but had no effect on total ERK1 protein levels (Fig.
3B). Ovariectomy had no significant effect on ERK2 pro-
tein levels or ERK2 phosphorylation (Fig. 3B).
Compared with ovariectomy, lower urinary tract 
inflammation had similar effects on p38 but not ERK
Chronic lower urinary tract inflammation, i.e. CYP treat-
ment for 10 days, caused a similar effect on p38 MAP
kinase as ovariectomy. That is, inflammation alone
caused a small increase in p38 protein expression (relative
to β-tubulin), however after inflammation there was no
parallel increase in p38 phosphorylation (Fig. 4A). More-
over, the inflammation-induced increase in p38 protein
was not influenced by prior ovariectomy (Fig. 4A).
Inflammation caused an increase in both phospho-ERK1
and phospho-ERK2 but when corrected for loading con-
trols (total ERK1 and ERK2) there was no net effect on
phosphorylation of either enzyme (Fig. 4B). These meas-
urements were not significantly affected by prior ovariec-
tomy (Fig. 4A, B).
Discussion
We have made a number of novel findings that reveal the
complexity of estrogenic actions and inflammation in
lumbosacral dorsal root ganglia (DRG) and suggest
potential strategies for modulating the activity of these
neurons in order to attenuate afferent hyperactivity or
pain states. In summary, in lumbosacral DRG acute treat-
ment with ER agonists initiated rapid phosphorylation of
p38 MAP kinase, whereas prolonged estrogen deprivation
in vivo (ovariectomy) did not have a long-lasting effect on
p38 MAP kinase phosphorylation; instead it caused an
increase in p38 expression. It has previously been
reported that estradiol causes rapid activation of ERK1/2
in adult rat DRGs [19]. In the present study, prolonged
estrogen deprivation in vivo had no effect on expression of
ERK1/2 in DRGs but caused their prolonged phosphoryla-
tion. There were some similarities in the effects of inflam-
mation but the responses were generally smaller or failed
to reach statistical significance. It is important to recognise
that whereas ovariectomy may influence a broader range
MAP kinase expression and activation in extracts of DRG  removed from control rats and four weeks after ovariectomy  (ovx) Figure 3
MAP kinase expression and activation in extracts of 
DRG removed from control rats and four weeks after 
ovariectomy (ovx). For each type of MAP kinase, the 
group data is shown with the Western blot for all samples, 
run at the same time. A, Relative to β-tubulin measurements 
in the same extract, levels of total p38 protein were 
increased after ovx but there was no evidence for increased 
phosphorylation. B, Relative to β-tubulin measurements in 
the same culture, there was no effect of ovx on ERK1 
expression but phosphorylation was enhanced; in contrast, 
ovx had no effect on expression or phosphorylation of ERK2. 
Results represent tissues from 4 rats per group. The same 
DRG extracts were used for analysis of p38 and ERK1/2. ** P 
< 0.05, ** P < 0.01, relative to control.
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of neurons, CYP treatment is likely to target only a small
proportion of neurons present in the DRG extracts (i.e.,
neurons innervating the lower urinary tract), so the
actions on MAP kinase signalling less readily identified.
The effects of CYP treatment may be larger if bladder-spe-
cific neurons could be studied separately, or if upper lum-
bar and sacral neurons were distinguished.
There are a growing number of examples of rapid actions
of estrogen in the nervous system; the mechanisms are
diverse and vary considerably between different types of
tissues [18,37]. While not yet examined extensively, rapid
effects of estrogens have also been reported in DRG,
including an action on intracellular calcium levels and
ATP-induced calcium currents [38-40], as well as ER-
dependent ERK and CREB phosphorylation [19]. In the
present study, the effect of estradiol to rapidly stimulate
p38 phosphorylation in DRG neurons in short-term cul-
ture was mimicked by agonists of ERα and ERβ, which in
vivo are co-expressed by many lumbosacral DRG neurons
[16]. Involvement of ER in this response is also indicated
by the blockade by tamoxifen. The transient nature of a
rapid response to a single application of estrogen applied
in vitro may not reflect the nature of estrogen actions in
vivo, where levels may change more slowly due to changes
in circulating hormones (e.g. during the estrous or men-
strual cycles) or local production from aromatase-express-
ing target tissues. Nevertheless these observations are, to
our knowledge, the first to indicate the ability of estrogens
to active p38 MAP kinase in sensory ganglia.
There are numerous reports of rapid, ER-dependent acti-
vation of p38 signalling in non-neuronal cells (e.g. [41-
43]). However, in the current study we may have identi-
fied a novel mechanism of ER-dependent p38 activation,
suggested by the observation that the ER-antagonist,
ICI182780, not only mimicked but also enhanced the
estrogen response. An "estrogen agonist" effect of
ICI182780 has been observed previously in rat DRG,
where estradiol inhibition of TRPV1 activity was inhibited
by tamoxifen but mimicked by ICI182780 [17]. However,
in this earlier study, estrogen agonists and ICI182,780
were each administered to neurons for a much longer
period (overnight), which allowed the consideration of a
larger variety of possible contributing mechanisms. The
"agonist" effect of overnight treatment with ICI182,780
could be due to "tethering" of ER with transcription fac-
tors, (e.g., AP-1, STAT5) that affects the nature of subse-
quent actions with various agents, including ICI182,780
[44]. However, in the current study, our rapid treatment
with these agents makes this mechanism less likely so
many additional molecular studies will need to be per-
formed to determine the basis of ICI182,780 actions. It is
also possible that the effects of ICI182,780 observed here
MAP kinase expression and activation in extracts of DRG  removed from control rats, rats with bladder inflammation  (cyclophosphamide treatment, cyp) and bladder inflammation  evoked four weeks after ovariectomy (cypovx) Figure 4
MAP kinase expression and activation in extracts of 
DRG removed from control rats, rats with bladder 
inflammation (cyclophosphamide treatment, cyp) 
and bladder inflammation evoked four weeks after 
ovariectomy (cypovx). For each MAP kinase, the group 
data is shown with the Western blot for all samples, run at 
the same time. A, Relative to β-tubulin measurements in the 
same culture, levels of total p38 protein were increased after 
cyp and cypovx but there was no evidence for increased 
phosphorylation. B, Relative to β-tubulin measurements in 
the same culture, there was no effect of cyp or cypovx on 
ERK1 and ERK2 expression but phosphorylation of each was 
enhanced. Number of rats per group: control = 4, cyp = 5, 
cypovx = 3. The same DRG extracts were used for analysis 
of p38 and ERK1/2. ** P < 0.05, ** P < 0.01, relative to con-
trol.
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are independent of ER, although this agent is widely con-
sidered to be highly specific for these receptors.
Our studies examining the impact of chronic estrogen
deprivation and inflammation revealed further complex-
ity in the modulation of MAP kinase signalling pathways
in lumbosacral sensory ganglia. Estrogen deprivation for 4
weeks following ovariectomy caused quite different effects
on p38, ERK1 and ERK2 signalling pathways from the
rapid treatment with estrogen. These showed an upregula-
tion of p38 expression (but not phosphorylation),
increased ERK1 phosphorylation (but not expression)
and no change in ERK2 expression or phosphorylation. A
change in expression of any of the MAP kinases has not
commonly been reported after neuronal perturbation and
the physiological implications of this are unknown.
The dissimilar actions we observed on each type of MAP
kinase are of particular interest in light of a recent study on
the effects of bee venom-induced inflammation and
hyperalgesia on spinal cord neurons, which showed dis-
tinct kinetics of activation for each MAP kinase, i.e. ERK
activation occurs rapidly (up to 1 day) after challenge but
p38 activation occurs more slowly (1-7 days) [45]. This
study also showed a spatial difference in the ERK and p38
activation patterns within the cord. In our study, the
greater effects of our manipulations on ERK1 than ERK2
were unexpected, as numerous studies report parallel
changes in these two signalling pathways following cell
stimulation. However, recent studies have not only iden-
tified functional differences in ERK1 and ERK2 [46] and
distinct consequences of ERK1 and ERK2 loss [47-49], but
also described the structural bases for their functional dif-
ferences [50]. It is possible that different populations of
pelvic nociceptors also show distinct responses.
Previous studies of somatic inflammation have demon-
strated an effect on phosphorylation of both ERK and p38
MAP kinases (reviewed in [22]). Our results show that
prolonged (10-day) visceral inflammation caused only a
very modest effect on phospho-ERK levels in lumbosacral
DRG, an effect that did not achieve statistical significance
when loading controls (total ERK) were considered. An
earlier study using a similar model of bladder inflamma-
tion in rats did not detect a comparable change in ERK1/
2 phosphorylation in lumbosacral DRG, although they
did report a transient (up to 48 h) increase in ERK5 acti-
vation [51].
In the current study we could not directly assess the
impact of estrogen status on the subsequent response to
inflammation because ovariectomy alone caused effects
on p38 and ERK MAP kinases. The possibility that these
two perturbations activate convergent modulatory mech-
anisms should be explored further, particularly given the
recent observation that some symptoms resembling
aspects of interstitial cystitis develop in ERβ-knockout
mice [52]. It is also possible that local estrogen produc-
tion (e.g. in the spinal cord dorsal horn or in peripheral
tissues [53]) impacts on modulation of neuronal signal-
ling by inflammation. Conversely, inflammation of the
lower urinary tract may impact on circulating estrogen lev-
els or local estrogen production. Moreover, estrogens have
a complex role in modulating inflammation [54], so the
nature of cyclophosphamide-induced cystitis may not be
the same in ovariectomised animals.
Conclusions
This study has revealed novel patterns of activation of p38
and ERK MAP kinases in lumbosacral dorsal root ganglia
following acute exposure in vitro or chronic deprivation of
estrogens in vivo. The diversity of estrogen actions in these
ganglia that have a major role in pelvic visceral pain raises
the possibility of developing new ways to modulate their
function in hyperactivity or pain states.
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